Given (1) autophagy is a major cellular pathway for the removal of β and aggregated proteins, and (2) cilostazol stimulates the expression and activity of SIRT1; we hypothesized that the therapeutic use of cilostazol to enhance the autophagy pathway might provide an attractive pharmacological direction for decreasing intracellular Aβ and APP-CTFβ levels in AD. This evidence concerns the gene SIRT1 and Alzheimer disease.